Replicor reveals clinical trial data at Global Virus Hepatitis Summit
The updated data included new effectiveness and safety data involving patients who completed a combination therapy phase with REP 2139-Ca and Pegasys. This phase took place before completing the REP 2139-Ca monotherapy. The subsequent data shows the ongoing elimination of HDV RNA serum throughout the combination treatment in all of the patients.
The three earlier Asian clinical trials as well as the data from the Caucasian REP 301 trial show that REP 2139 can be used by itself or in conjunction with ZADAXIN or Pegasys. Antiviral responses are profound when using REP 2139-Ca as the therapy backbone combination alongside a variety of ETV and immunotherapies.
The company chose Andrew Vaillant, the chief scientific officer of the company, as its representative. His presentation was given at the 15th International Symposium on Viral Hepatitis and Liver Disease in Berlin. This conference convenes every three years to discuss new developments in treating viral hepatitis.